Logo

argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Share this
argenx

argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Shots:

  • The US FDA has accepted and granted priority review to argenx’s sBLA of Vyvgart Hytrulo for treating chronic inflammatory demyelinating polyneuropathy (CIDP) with the decision anticipated on Jun 21, 2024
  • The sBLA was based on the data from (ADHERE) trial investigating the safety and efficacy of Vyvgart Hytrulo (SC) vs PBO for treating CIDP adults (n=322)
  • The results revealed lower relapse risk by 61%, evidence of clinical improvement in 67% of patients across the trial’s open-label Stage A and the role of IgG autoantibodies in the underlying biology of CIDP based on the drug’s MOA. 226/228 patients progressed in the (ADHERE-+) extension trial after the (ADHERE) study

Ref: argenx | Image: argenx

Related News:- Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions